We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

900932:SSEShanghai Lujiazui Finance & Trade Zone Development Co., Ltd. Class B Analysis

Data as of 2026-06-02 - not real-time

$0.38

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Shanghai Lujiazui Finance & Trade Zone Development is trading at a steep discount to its intrinsic estimate, with the market price well below the discounted cash‑flow target and a price‑to‑book ratio under one. Technical gauges point to short‑term weakness – the 20‑day moving average sits beneath the 50‑day, the RSI is in oversold territory and the MACD histogram remains negative, while volume has been tapering, suggesting limited buying pressure. Despite this, the stock offers an unusually high dividend yield that is supported by a strong cash position, though the payout ratio is near full, raising questions about sustainability.
The balance sheet is heavily levered, with debt dwarfing equity, and the company has posted a sharp decline in revenue, reflecting broader challenges in China’s real estate sector and heightened regulatory scrutiny. These fundamentals, combined with modest beta and elevated volatility, create a mixed risk profile: the valuation appears attractive for value‑oriented investors, but the high leverage and sector headwinds temper enthusiasm.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish technical momentum with negative MACD and declining volume
  • Price hovering near recent support levels
  • Uncertainty around dividend continuity

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant valuation discount relative to intrinsic estimate
  • High debt burden limiting operational flexibility
  • Potential stabilization in the Chinese real‑estate environment

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Deep valuation gap offering upside potential
  • Strong cash reserves to support dividend and debt service
  • Long‑run recovery prospects for the sector as policy eases

Key Metrics & Analysis

Financial Health

Revenue Growth-47.20%
Profit Margin4.91%
P/E Ratio18.8
ROE1.73%
ROA1.02%
Debt/Equity146.59
P/B Ratio0.5
Op. Cash Flow$12.6B
Free Cash Flow$11.1B
Industry P/E31.7

Technical Analysis

TrendBearish
RSI36.9
Support$0.37
Resistance$0.41
MA 20$0.38
MA 50$0.39
MA 200$0.42
MACDBearish
VolumeDecreasing
Fear & Greed Index92.61

Valuation

Fair Value$17.81
Target Price$0.66
Upside/Downside74.83%
GradeUndervalued
TypeValue
Dividend Yield7.85%

Risk Assessment

Beta0.22
Volatility16.62%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.